gabaa receptor β3 (PhosphoSolutions)
PhosphoSolutions is a verified supplier 
PhosphoSolutions manufactures this product 
96
Structured Review
PhosphoSolutions
gabaa receptor β3
Gabaa Receptor β3, supplied by PhosphoSolutions, used in various techniques. Bioz Stars score: 96/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gabaa receptor β3/product/PhosphoSolutions
Average 96 stars, based on 3 article reviews
Gabaa Receptor β3, supplied by PhosphoSolutions, used in various techniques. Bioz Stars score: 96/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gabaa receptor β3/product/PhosphoSolutions
Average 96 stars, based on 3 article reviews
gabaa receptor β3 - by Bioz Stars,
2026-06
96/100 stars
Images
1) Product Images from "Inhibitory and excitatory synaptic neuroadaptations in the diazepam tolerant brain."
Article Title: Inhibitory and excitatory synaptic neuroadaptations in the diazepam tolerant brain.
Journal: Neurobiology of disease
doi: 10.1016/j.nbd.2023.106248
Figure Legend Snippet: Fig. 2. Synaptic and extrasynaptic GABAA receptor and gephyrin redistribution with seven-day DZP treatment in vivo. (A-F) Mice were treated i.p. once daily for seven days with Veh or DZP. Western blot analysis of collected cortical tissue was performed to assess protein levels of GABAAR subunits and gephyrin from total (A, B), synaptic (C, D), and extrasynaptic (E, F) fractions. Representative blots show five mice from each treatment group. Proteins quantified by western blot were normalized to GAPDH or KIR3.2 loading control. (B) Measurements of total protein levels revealed a significant increase in α1 (p = 0.0018), β3 (p = 0.0005), and γ2 (p = 0.0002) subunits. The amount of synaptic α1 (p = 0.0019), α4 (p = 0.0028), and γ2 (p = 0.0007) subunits also increased (D), while extrasynaptic α1 (p = 0.0034) and α4 (p = 0.0010) subunits were decreased and gephyrin (p = 0.0040) was increased (F) (*p ≤0.05, **p < 0.01, ***p < 0.001, Student’s t-test; n = 5–10 mice per treatment; error bars ± S.E.M.).
Techniques Used: In Vivo, Western Blot, Control
Figure Legend Snippet: Fig. 3. γ2 containing GABAA receptor composition is unchanged and tonic inhibition is reduced in DZP mice. (A) Immunoprecipitation of γ2-GABAAR from seven-day Veh- or DZP-treated mouse cortex was analyzed by DIA mass spectrometry to assess changes in receptor subunit composition (n = 4 mice per treatment group). The intensity of α1–5 subunit-specific peptides are shown. Inset: Relative abundance (%) of α and β subunits associated with γ2 after seven-day DZP treatment. (B,C) (B) Left: representative traces with mIPSCs from seven-day DZP-treated animals before (dark red) and after (gray) 300 nM Ro 15–4513 application. Right: averaged mIPSCs before and after Ro 15–4513. (C) Quantification shows inverse agonist activity of Ro 15–4513, consistent with predominant receptors composed of γ2 with α1, α2, α3, α5-GABAAR subunits (n = 5 cells; amplitude, p = 0.0191; frequency, p = 0.0179; tau, p = 0.0026). (D) GABAAR-mediated tonic current was measured in acute cortical slices from mice treated i.p. once daily for seven days with Veh or DZP. Picrotoxin-sensitive changes in holding current (Vhold = −70 mV) were used to measure tonic inhibition in cortical slices from seven-day Veh- or DZP-treated mice. (E) Quantification revealed that GABAAR-mediated tonic current was significantly reduced (p = 0.0084) in DZP-treated mice (n = 8) relative to Veh-treated mice (n = 6). (E: **p ≤0.01, Student’s t-test; C: *p ≤ 0.05, **p ≤0.01, paired t-test; error bars ± S.E.M.).
Techniques Used: Inhibition, Immunoprecipitation, Mass Spectrometry, Activity Assay